We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-3.93%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
-$117M
Cap. Flow
-$19.9M
Cap. Flow %
-1.66%
Top 10 Hldgs %
63.36%
Holding
73
New
12
Increased
16
Reduced
13
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$32M
2
NVO
Novo Nordisk
NVO
+$30.4M
3
IRTC icon
iRhythm Holdings
IRTC
+$18.8M
4
SNY icon
Sanofi
SNY
+$15M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$13.8M

Top Sells

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$20.1M
2
UTHR icon
United Therapeutics
UTHR
+$18.9M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$18.3M
4
GH icon
Guardant Health
GH
+$15.9M
5
AZN icon
AstraZeneca
AZN
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$262M 21.84%
2,073,124
+120,047
+6% +$13.8M
NTRA icon
2
Natera
NTRA
$37.5B
$110M 9.16%
3,102,960
– –
CINC
3
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$105M 8.75%
5,573,949
– –
JBIO
4
Jade Biosciences
JBIO
$1.22B
$58.7M 4.89%
107,391
– –
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$46.5M 3.87%
499,824
– –
VERA icon
6
Vera Therapeutics
VERA
$2.54B
$43.3M 3.61%
3,181,442
– –
XLV icon
7
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
$38.5M 3.2%
+300,000
New +$39.3M
YMAB
8
DELISTED
Y-mAbs Therapeutics
YMAB
$33.2M 2.76%
2,194,278
– –
MRK icon
9
Merck
MRK
$324B
$32.9M 2.74%
+360,961
New +$32M
NVO
10
Novo Nordisk
NVO
$216B
$30.5M 2.54%
+547,746
New +$30.4M
XBI icon
11
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$29.7M 2.47%
400,000
+200,000
+100% +$15M
UTHR icon
12
United Therapeutics
UTHR
$26.3B
$25.1M 2.09%
106,379
-92,804
-47% -$18.9M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.5B
$25M 2.08%
301,605
+125,072
+71% +$9.96M
RETA
14
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$23.8M 1.98%
783,851
+181,306
+30% +$5.41M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$121B
$21.1M 1.75%
74,758
-20,245
-21% -$5.42M
AZN icon
16
AstraZeneca
AZN
$263B
$20.9M 1.74%
158,180
-118,772
-43% -$15.6M
RGNX icon
17
Regenxbio
RGNX
$623M
$19.2M 1.6%
776,624
+162,539
+26% +$4.06M
INZY
18
DELISTED
Inozyme Pharma
INZY
$17.4M 1.45%
3,655,308
+1,627,000
+80% +$7.08M
CTIC
19
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$16.1M 1.34%
2,704,510
+751,819
+39% +$3.85M
CCXI
20
DELISTED
ChemoCentryx, Inc.
CCXI
$15.8M 1.31%
636,659
+62,975
+11% +$1.39M
IRTC icon
21
iRhythm Holdings
IRTC
$3.59B
$15.3M 1.28%
+142,091
New +$18.8M
SNY icon
22
Sanofi
SNY
$104B
$14.1M 1.18%
+282,200
New +$15M
DXCM icon
23
DexCom
DXCM
$27.6B
$14.1M 1.17%
189,092
+28,032
+17% +$2.56M
CYTK icon
24
Cytokinetics
CYTK
$11B
$12.6M 1.05%
320,780
+257,836
+410% +$10.4M
NXTC icon
25
NextCure
NXTC
$17.3M
$12.6M 1.05%
222,655
– –
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Sofinnova Investments held 73 positions worth $1.2B, down 8.9% from $1.32B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sofinnova Investments's Q2 2022 filing shows 12 new, 16 increased, 13 reduced and 15 closed positions. Its largest new stake was Merck: 360,961 shares worth $32.9M. The largest sale was Zoetis, an estimated $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier.

  • Sofinnova Investments's largest Q2 2022 buy was Merck: 360,961 shares worth $32.9M.
  • Sofinnova Investments added most to Karuna Therapeutics, Inc. Common Stock in Q2 2022, an estimated $13.8M increase.
  • Sofinnova Investments's biggest Q2 2022 reduction was United Therapeutics, cutting an estimated $18.9M.
  • Sofinnova Investments fully exited Zoetis in Q2 2022, selling an estimated $20.1M.
  • Sofinnova Investments's ten largest holdings make up 63% of its $1.2B portfolio in Q2 2022.
  • Sofinnova Investments opened 12 new positions and closed 15 in Q2 2022.
  • Sofinnova Investments's portfolio value fell 8.9% quarter-over-quarter to $1.2B.

Based on Sofinnova Investments's 13F filing for Q2 2022, filed 15 Aug 2022.